Company / Return on Equity (ROE)
Apellis Pharmaceuticals, Inc. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
6.0%
FY2025
5-year range
-383.9% / 6.0%
FY2021-FY2025
Trend
+107.0%
vs FY2024
Sector context
#42 of 190
Health Care
What the data says
Apellis Pharmaceuticals, Inc.'s return on equity (roe) of 6.0% is higher than 78% of companies in the Health Care sector (FY2025). Return on Equity (ROE) has increased for 3 consecutive years, from -383.9% in FY2022 to 6.0% in FY2025.
Based on SEC 10-K filings.
6.0% in FY2025 with a 5-year CAGR of +174.7%. Top quartile in the Health Care sector.
Improved from -271.8% to 6.0% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +390.0pp
- 5-Year Change
- +174.7pp
- 10-Year Change
- -
Sector benchmark
+112.0% above sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s return on equity (roe) has grown for 3 consecutive years.
- In FY2025, return on equity (roe) increased 107.0% year-over-year.
- Currently 56.4pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 6.0% | +107.0% |
| FY2024 | -86.6% | +68.1% |
| FY2023 | -271.8% | +29.2% |
| FY2022 | -383.9% | -2.2% |
| FY2021 | -375.7% | -122.8% |
| FY2020 | -168.6% | - |
| FY2019 | - | - |
| FY2018 | -79.2% | -131.3% |
| FY2017 | -34.3% | +70.0% |
| FY2016 | -114.0% | +14.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026